General Myositis Studies

The following list of published research is intended to serve as a resource for study of inflammatory myopathies.

2018

• Helene Alexanderson. Exercise in Myositis . Curr Treat Options in Rheum. 2018; 4:289–298.  DOI 10.1007/s40674-018-0113-3
• Vuillard C, de Chambrun MP, de Prost N, Guérin C, Schmidt M, Dargent A, Quenot J-P, Préau S, Ledoux G, Neuville M, Voiriot G, Fartoukh M, Coudroy R, Dumas G, Maury E, Terzi N, Tandjaoui‑Lambiotte Y, Schneider F, Grall M, Guérot E, Larcher R, Ricome S, Le Mao R, Colin G, Guitton C, Zafrani L, Morawiec E, Dubert M, Pajot M, Mentec H, Plantefève G, Contou D. Clinical features and outcome of patients with acute respiratory failure revealing anti‑synthetase or anti‑MDA‑5 dermato‑pulmonary syndrome: a French multicenter retrospective study.  Annals of Intensive Care. 2018; 8:87. https://doi.org/10.1186/s13613-018-0433-3.
• Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohme A, Charuel J-L, Musset L, Allenbach Y, Benveniste O. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies.  JAMA Neurology. September 10, 2018. https://doi:10.1001/jamaneurol.2018.2598
• Krauss A. Why all randomised controlled trials produce biased results 2018. Annals of Medicine. 2018. DOI: 10.1080/07853890.2018.1453233

2017

• Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C,  Silhan L, Christopher-Stine L, Mammen AL, and Danoff SK. A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 2017;56:999-1007.  doi:10.1093/rheumatology/kex021.
• Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017 Mar 20;3(1):e000412. doi: 10.1136/rmdopen-2016-000412.
• Michal Feldon, Payam Noroozi Farhadi, Hermine I. Brunner, Lukasz Itert, Bob Goldberg, Abdullah Faiq, Jesse Wilkerson, Kathryn M. Rose, Lisa G. Rider, Frederick W. Miller, Edward H. Giannini. Predictors of reduced health-related quality of life in adult patients with idiopathic inflammatory myopathies. Arthritis Care & Research. 2017. DOI 10.1002/acr.23198.
• Jessica F. Boehler, Marshall W. Hogarth, Matthew D. Barberio, James S. Novak, Svetlana Ghimbovschi, Kristy J. Brown, Li Alemo Munters, Ingela Loell, Yi-Wen Chen, Heather Gordish-Dressman, Helene Alexanderson, Ingrid E. Lundberg, Kanneboyina Nagaraju. Effect of endurance exercise on microRNAs in myositis skeletal muscle: A randomized controlled study. PLoS ONE. 2017, 12(8): e0183292.  DOI: 10.1371/journal.pone.0183292
• Alexander Oldroyd, James Lilleker, Hector Chinoy. Idiopathic inflammatory myopathies: A guide to subtypes, diagnostic approach and treatment. Clinical Medicine. 2017, 17(4): 322–8.
• IE Lundberg, A Tjärnlund, M Bottai, VP Werth, C Pilkington, M de Visser, L Alfredsson, AA Amato, RJ Barohn, MH Liang, JA Singh, R Aggarwal, S Arnardottir, H Chinoy, RG Cooper, K Dankó, MM Dimachkie, BM Feldman, I Garcia-De La Torre, P Gordon, T Hayashi, JD Katz, H Kohsaka, PA Lachenbruch, BA Lang, Y Li, CV Oddis, M Olesinska, AM Reed, L Rutkowska-Sak, H Sanner, A Selva-O’Callaghan, Y-W Song, J Vencovsky, SR Ytterberg, FW Miller, LG Rider, The International Myositis Classification Criteria Project consortium, The Euromyositis register, and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, October 27. DOI:10.1136/annrheumdis-2017-211468.
• T Morel1, SJ Cano. Measuring what matters to rare disease patients: Reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet Journal of Rare Diseases. 2017, 12:171. DOI 10.1186/s13023-017-0718-x.

2016

• Nahin RL, Boineau R, Khalsa PS, Stussman BJ, Weber WJ. Evidence-based evaluation of complementary health approaches for pain management in the United States. Mayo Clin Proc. 2016. 91(9):1292-1306. doi.org/10.1016/j.mayocp.2016.06.007.
• H. Alexanderson.  Physical exercise as a treatment for adult and juvenile myositis.  Journal of Internal Medicine.  doi: 10.1111/joim.12481.
• I. E. Lundberg.  New ways to subclassify patients with myositis.  Journal of Internal Medicine.  DOI: 10.1111/joim.12515.
• H. Alexanderson. Physical exercise as a treatment for adult and juvenile myositis.  Journal of Internal Medicine.   DOI: 10.1111/joim.12481.
• C. V. Oddis.  Update on the pharmacological treatment of adult myositis.  Journal of Internal Medicine.  DOI: 10.1111/joim.12511.
• I. E. Lundberg, F. W. Miller, A. Tjarnlund and M. Bottai.  Diagnosis and classification of idiopathic inflammatory myopathies.  Journal of Internal Medicine.  DOI: 10.1111/joim.12524.
• Z. Betteridge and N. McHugh.   Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.   Journal of Internal Medicine.  DOI: 10.1111/joim.12451
• Thomas Schwartz, Louise Pyndt Diederichsen, Ingrid E Lundberg, Ivar Sjaastad & Helga Sanner.  Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies.  RMD Open 2016 2: doi: 10.1136/rmdopen-2016-000291.
• Orlandi M, Barsotti S, Cioffi E, Tenti S, Toscano C, Baldini C, Neri R. One year in review 2016: idiopathic inflammatory myopathies. Clin Exp Rheumatol 2016; 34: 966-974.

2015

• Shirley Pulawski.  Patients’ demographic, comorbidity profiles vary considerably by myositis subtype.  Faiq A, et al. Paper #2211. Presented at: American College of Rheumatology Annual Meeting. Nov. 14-19, 2014; Boston.
• Ingrid E. Lundberg, Jiri Vencovsky, and Helene Alexanderson. Therapy of myositis: biological and physical.  www.co-rheumatology.com. Volume 26 Number 6 November 2014.
• Abdullah Faiq, Payam Noroozi Farhadie, Frederick W. Miller, Nastaran Byatt and Lisa G. Rider of the Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD; Jesse Wilkerson, Social and Scientific Systems, Inc., Research Triangle Park, NC; Anna Jansen, NIEHS/EAG Bethesda, MD; Richard Morris and Kathryn Rose of Social and Scientific Systems, Inc, Durham, NC; Lukasz Itert, Anne Johnson and Edward Giannini of Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Christine Parks, NIEHS, NIH, Research Triangle Park, NC; Hermine I. Brunner, PRCSG, Cincinnati, OH; Bob Goldberg, The Myositis Association, Alexandria, VA.  Myovision Predictors.  “Myovision Predictors. This was presented at the 2014 American College of Rheumatologists annual meeting.
• Webber MP, Moir W, Zeig-Owens R, Glaser MS, Jaber N, Hall C, Berman J, Qayyum B, Loupasakis K, Kelly K, Prezant DJ.  Nested Case-Control Study of Selected Systemic Autoimmune Diseases in World Trade Center Rescue/Recovery Workers.  Arthritis Rheumatol. 2015 Mar 16. doi: 10.1002/art.39059.
• Clara Crescioli.  Vitamin D Receptor Agonists: Suitable Candidates as Novel Therapeutic Options in Autoimmune Inflammatory Myopathy.  Biomed Res Int.  2014; 2014: 949730.  Published online 2014 May 7. doi: 10.1155/2014/949730.
• Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti-Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. Plos One November 5, 2015. DOI:10.1371/journal.pone.0133702.
• Siamak Moghadam-Kia, Rohit Aggarwal, and Chester V. Oddis. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol. 2015; 11(11): 1265–1275. doi:10.1586/1744666X.2015.1082908.

2014

• David Isenberg.  Newfound explanations for myositis.  rheumatology network.  September 30, 2014.
• Jemima Albayda and Lisa Christopher-Stine. Identifying statin-associated autoimmune necrotizing myopathy. Cleveland Clinic Journal of Medicine. 2014 December; 81(12):736-741.

2013

• Sabrina Paganoni and Anthony Amato.  Electrodiagnostic Evaluation of Myopathies.  Phys Med Rehabil Clin AM.  24 (2013) 193-207.  http://dx.doi.org/10.1016/j.pmr.2012.08.017.
• William Coley, Sree Rayavarapu and Kanneboyina Nagaraju.  Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies.  Arthritis Research and Therapy.  Coley et al. Arthritis Research & Therapy 2012, 14:209.  http://arthritis-research.com/content/14/2/209

2012

• Frederick W Miller.  New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71(SuppII):i82-i85. doi:10.1136/annrheumdis-2011-200587.
• Li Alemo Munters, Ronald F. van Vollenhoven, and Helene Alexanderson.  Patient Preference Assessment Reveals Disease Aspects Not Covered by Recommended Outcomes in Polymyositis and Dermatomyositis. International Scholarly Research Network. ISRN Rheumatology. Volume 2011, Article ID 463124, 5 pages doi:10.5402/2011/463124.
• Helene Alexanderson and Ingrid E. Lundberg.  Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Current Opinion.
• David J. Gazeley and Mary E. Cronin.  Diagnosis and treatment of the idiopathic inflammatory myopathies.  Ther Adv Musculoskeletal Disease.  2011 December; 3(6): 315-324
• Christine Castro adn Mark Gourley.  Diagnosis and treatment of inflammatory myopathy:  issues and management.  Ther Adv Musculoskeletal Disease.  2012 April; 4(2):  111-120.
• Jemima Albayda and Lisa Christopher-Stine.  Novel approaches in the treatment of myositis and myopathies.  Ther adv musculoskeletal Disease.  2012 October; 4 (5):  369-377.

2011

• B. Jane Distad, MD, Anthony A. Amato, MD, Michael D. Weiss, MD.  Inflammatory Myopathies. Current Treatment Options in Neurology. 08 January 2011. DOI 10.1007/s11940-010-0111-8.
• Geoffrey Connors, MD; Lisa Christopher-Stine, MD; Chester Oddis, MD and Sonye Danoff, MD.  Interstitial Lung Disease Associated with the Idiopathic Inflammatory Myopathies. CHEST 2010; 138(6):1464-1474.
• I. Loell and I.E. Lundberg.  Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? 2011 The Association for the Publication of the Journal of Internal Medicine. doi: 10.1111/j.1365-2796.2010.02334.x

2010

• Marinos C Dalakas.  Inflammatory muscle disease: a critical review of pathogenesis and therapies. Current Opinion in Pharmacology (2010), 10:1-7. DOI 10.1016/j.coph.2010.03.001.
• Meena Kalluri, MD, Chester V. Oddis, MD.  Pulmonary Manifestations of the Idiopathic Inflammatory Myopathies. Clin Chest Med 31 (2010) 501-512. doi:10.1016/j.ccm.2010.05.008.

2006-2008

• I.E. Lunberg & C.J. Forbess. Mortality in Myositis. Clinical and Experimental Rheumatology. 2008; S 109-114.
• Ingrid E lundberg & Gustavo A Nader.  The Effects of Exercise in Inflammatory Rheumatic Disease. Nature Clinical Practice Rheumatology. 2008; 1-8.
• Terrance P. O’Hanlon, Lisa G. Rider, Gulnara Mamyrova, Ira N. Targoff, Frank C. Arnett, John D. Reveille, Mary Carrington, Xiaojiang Gao, Chester V. Oddis, Penelope A. Morel, James D. Malley, Karen Malley, Ejaz A. Shamim, Stephen J. Chanock, Charles B. Foster, Thomas Bunch, Ann M. Reed, Lori A. Love, Frederick W. Miller. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis & Rheumatism. 2006; 54(11): 3670–3681. DOI 10.1002/art.22205.

2001-2005

• Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci (2003) 24:S256–S259.

1991-1995

• Mastaglia FL, et al. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 65: 107-110, 1998.

1980-1990

• Cronin ME, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16: 1225-1228, 1989.